John Lisman is an attorney at the Netherlands-based international law firm, NautaDutilh. He focuses on issues relating to the marketing authorisation, pricing and reimbursement of medicinal products and medical technology, both nationally and at the level of the European Union. From 1992 until 1999 he was a senior staff member at the Department of Pharmaceutical Affairs in the Ministry of Health and from 1999 until 2007, he was a policy advisor and legal counsel at the Medicines Evaluation Board. During these years, Mr Lisman was a member of the EU Pharmaceutical Committee, the Management Board of the EMEA and the Standing Committee for medicinal products. He was involved in the drafting of the new EU pharmaceutical legislation which took effect in 2004. Mr Lisman publishes regularly in legal and regulatory journals and frequently gives lectures. He is on the editorial board of the Dutch journal “Jurisprudentie Geneesmiddelenrecht” (Pharmaceutical Case Law) and of MedNous. He is also a board member and co-founder of the Dutch Association for Pharmacy and Law and co-chair and founder of the Legal Affairs Special Interest Area Community of the Drug Information Association. Mr Lisman received his masters degree in Pharmaceutical Sciences from Utrecht University in 1985. In 1988, he graduated in Dutch Law from the same university. Mr Lisman is based in Amsterdam, the Netherlands.